Firebrick Pharma Limited (AU:FRE) has released an update.
Firebrick Pharma Limited has issued 360,000 new shares following the exercise of options, as part of their financial strategy without investor disclosure, under specific conditions of the Corporations Act. Simultaneously, the company is seeking international market approval for its innovative Nasodine Nasal Spray, although it has not disclosed the target country. Firebrick Pharma has already made successful strides in the US and Singapore markets with this product, which has been backed by multiple patents and clinical trials.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.
